secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001558370-24-005767
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q1 total revenue $210M, net loss narrows to $91.6M; pipeline milestones on track
--------------------------------------------------------------------------------

- Q1 total revenue $210M (down ~5% YoY); DMD franchise $161M (Translarna $104M, Emflaza $57M).
- GAAP net loss $91.6M, improved from $139M loss in Q1 2023; cash $884.8M.
- Submitted MAA for sepiapterin (PKU) and BLA for Upstaza (AADC deficiency) in March 2024.
- Plans to resubmit Translarna NDA mid-2024; PIVOT-HD (PTC518) interim data in Q2 2024.
- Reaffirmed FY2024 total revenue guidance $600-680M; GAAP R&D/SG&A $740-835M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000155837024005767/0001558370-24-005767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000155837024005767/tmb-20240425x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-005767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer